February 25, 2011
SymBio Pharmaceuticals LimitedFuminori Yoshida
Representative Director
President and Chief Executive Officer

SymBio Pharmaceuticals Successfully Completes JPY2.0 Billion (USD24 Million) Series E
Private Placement
TOKYO, Japan, February 25, 2011 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo,President & CEO: Fuminori Yoshida, “SymBio”) announced today that the company has completed
a JPY2.0 billion (USD24 million) private placement of Series E common stock led by two existing
shareholders, Cephalon, Inc. and JAFCO Co., Ltd., a leading private equity firm in Japan.
In the pursuit of creating value for patients and shareholders, SymBio will use proceeds from thisfinancing round to accelerate the development of other hematological indications forbendamustine, including aggressive non-Hodgkin's lymphoma and multiple myeloma, to advancedevelopment of its granisetron transdermal patch for RINV/CINV, and to in-license other new
drug candidates as the company continues its geographical expansion in key Asian countries.
“I am extremely pleased that our two major shareholders continue to support our business at thisjuncture where SymBio needs capital to more aggressively expand into other Asia Pacificmarkets,” said Mr. Fuminori Yoshida, President and CEO. “In 2011, SymBio is being transformed
into a biopharmaceutical company with top-line revenue, multiple drug candidates in all stages ofdevelopment, and growing licensing opportunities. We will use proceeds from this round tomaximize the value for patients as well as shareholders."
Currently, SymBio has four drug candidates under development in its pipeline. The company’s
lead drug candidate, SyB L-0501 (bendamustine HCl), is an antineoplastic agent which received
Japan market approval in October, 2010 for the treatment of refractory/relapsed low-grade
non-Hodgkin’s lymphoma and mantle cell lymphoma. The approval of bendamustine HCl for theseindications was achieved within 4 years following enrollment of the first patient in its phase 1
study.
[Please read the following for further information on bendamustine hydrochloride, TREAKISYM,
Cephalon, and SymBio]
Exchange rate used: ¥83.28 = U.S. $1 as of February 14th, 2011.

Note to Editors

1. About Bendamustine HydrochlorideBendamustine hydrochloride was first synthesized in the early 1960s in the former ‘East Germany
Democratic Republic’ (GDR) by Jenapharm, and is currently marketed in Germany under thebrand name “Ribomustin®” as a treatment for non-Hodgkin’s lymphoma, multiple myeloma andchronic lymphocytic leukemia.
Mundipharma received marketing authorizations for bendamustine in several EU countries lastyear under the brand name “Levact®.” In the United States, the drug has been approved by theU.S. Food and Drug Administration (FDA) and is marketed by Cephalon as TREANDA® for thetreatment of chronic lymphocytic leukemia and relapsed indolent B-cell non-Hodgkin's lymphoma.
SymBio Pharmaceuticals Limited originally acquired the exclusive right from Astellas
Deutschland GmbH (Headquarters: Munich, Germany, formerly Astellas Pharma GmbH) todevelop and commercialize bendamustine in Japan (December, 2005), followed by signature of asecond license agreement for the exclusive right to China/Hong Kong, South Korea, Taiwan andSingapore (March, 2007).
2. About TREAKISYM®
Product Name:
TREAKISYM® for Injection, for intravenous infusion 100 mg
Generic Name:Bendamustine Hydrochloride
Indications and Usage:
For the treatment of relapsed or refractory forms of:▪ Low-grade B-cell non-Hodgkin’s lymphoma▪ Mantle cell lymphoma
Dosage and Administration:
The recommended dose in Japan is 120 mg/m2 administered intravenously over
60 minutes on Days 1 and 2 of a repeated 21-day cycle. The dosage may be
adjusted accordingly depending on the patient’s condition.
3. About Cephalon Inc.
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company with US
headquarters in Frazer, PA, and European headquarters located in Maisons-Alfort, France.
Since its inception in1987, Cephalon has delivered first-in-class and best-in-class medicines topatients around the world in several therapeutic areas. Cephalon has the distinction of being
one of the world’s fastest-growing biopharmaceutical companies, now among the Fortune 1000and member of the S&P 500 Index, and employing approximately 4,000 people worldwide.
Cephalon has the development and commercialization right to bendamustine hydrochloride in
United States, Canada, China and Hong Kong, receiving market approval from the FDA for thetreatment of chronic lymphocytic leukemia and relapsed indolent B-cell non-Hodgkin's lymphomain March and October of 2008, respectively.

For more information on Cephalon and their marketed products, please visit their website at
http://www.cephalon.com/
4. About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Ltd. was established in March, 2005 by Fuminori Yoshida, whopreviously served concurrently as Corporate VP of Amgen Ltd. and President of Amgen Japan(currently Takeda Bio Development Center Limited). The company’s underlying corporate mission
is “delivering hope to patients in need” as it aspires to be a leading specialty pharmaceuticalcompany in Asia Pacific dedicated to addressing underserved medical needs in the areas ofoncology, hematology and autoimmune disease.
[Contact]
SymBio Pharmaceuticals Limited.
Investor Relations, Finance & Accounting Department
Tel: +081(0)3 5472 1123
URL: http://www.symbiopharma.com/